Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: Insights from the NIRTOP study

Acute Cardiac Care

Volumn 10, Issue 2, 2008, Pages 104-110

  Kornowski, Ran ^a   Fort, Stephen ^b   Almagor, Yaron ^c   Silber, Sigmund ^d   Lewis, Basil S ^e  

^a RABIN MEDICAL CENTER   (Israel)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d Herzkatheterlabor   (Germany)

^e CARMEL MEDICAL CENTER   (Israel)

Author keywords

Diabetes; Restenosis; Revascularization; Stents

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION;

BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTHESIS FAILURE; RISK FACTORS; STENTS; TIME FACTORS;

EID: 45849142890     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940701787754     Document Type: Article

References (23)

1. Fort S, Kornowski R, Silber S, Lewis B, Bilodeau L, Almagor Y, et al. 'Fused-gold' versus 'bare' stainless steel NIRflex stents of the same geometric design in diseased Native coronary arteries - long term results from the NIRTOP study. Eurointervent (in press)
2. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584-9.
3. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-9.
4. Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 2004;109:2727-31.
5. Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J. 2003;145:1013-21.
6. Serruys P, Foley DP, de Feyter PJ. Quantitative coronary angiography in clinical practice. Dordrecht, the Netherlands: Kluwer Academic, 1994.
7. Ruygrok PN, Webster MW, Ardill JJ, Chan CC, Mak KH, Meredith IT, et al. Vessel caliber and restenosis: a prospective clinical and angiographic study of NIR stent deployment in small and large coronary arteries in the same patient. Catheter Cardiovasc Interv. 2003;59:165-71.
8. Hoffmann R, Mintz GS, Pichard AD, Kent KM, Satler LF, Leon MB. Intimal hyperplasia thickness at follow-up is independent of stent size: a serial intravascular ultrasound study. Am J Cardiol. 1998;82:1168-72.
9. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Hong MK, et al. Intravascular ultrasound assessment of the mechanisms and predictors of restenosis following coronary angioplasty. J Invasive Cardiol. 1997;9:303-14.
10. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995;91:2995-3001.
11. Edelman ER, Rogers C. Stent-versus-stent equivalency trials: are some stents more equal than others? Circulation. 1999;100:896-8.
12. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
13. Kornowski R, Lansky AJ. Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheter Cardiovasc Interv. 2000;50:245-54.
14. Safley DM, Marso SP. Diabetes and percutaneous coronary revascularization in the drug-eluting stent era. Herz. 2004;29:542-50.
15. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) study. Circulation. 2004;109:1366-70.
16. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
17. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
18. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989-97.
19. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. N Engl J Med. 2002;346:1773-80.
20. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al. Ravel Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J. 2004;25:107-12.
21. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Alfonso F, Ban̈uelos C, Goicolea J, et al. DIABETES and sirolimus eluting stent trial. Presented at TCT Meeting 9/2004.
22. Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon angioplasty revascularization investigation. J Am Coll Cardiol. 1997;30:1420-5.
23. Kornowski R, Fuchs S. Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions J Am Coll Cardiol. 2004;43:15-7.